Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, treosulfan (Trecondi®) cannot be endorsed for use within NHS Wales in combination with fludarabine prior to haematopoietic stem cell transplant as part of conditioning treatment prior to allogenic haematopoietic stem cell transplantation (alloHSCT) in adult patients with non-malignant diseases |
||
|
||
Medicine details |
||
| Medicine name | treosulfan (Trecondi®) | |
| Formulation | 50 mg/ml powder for solution for injection/infusion | |
| Reference number | 4404 | |
| Indication | For use in combination with fludarabine prior to haematopoietic stem cell transplant as part of conditioning treatment prior to allogenic haematopoietic stem cell transplantation (alloHSCT) in adult patients with non-malignant diseases |
|
| Company | medac GmbH | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 12/12/2019 | |
| Date of issue | 13/12/2019 | |